


Simvastatin hydroxy acid sodium

| | |
|--------------------|-------------------------------------------------------------------------------------------|
| Cat. No.: | HY-115292 |
| CAS No.: | 101314-97-0 |
| Molecular Formula: | C ₂₅ H ₃₉ NaO ₆ |
| Molecular Weight: | 458.56 |
| Target: | HMG-CoA Reductase (HMGCR) |
| Pathway: | Metabolic Enzyme/Protease |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



BIOLOGICAL ACTIVITY

| | |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Description | Simvastatin hydroxy acid sodium (Tenivastatin sodium; Simvastatin Impurity A sodium) is an active hydrolytic metabolite of Simvastatin (HY-17502) ^[1] . Simvastatin shows a inhibition of HMG-CoA reductase with a K _i value of 0.12 nM ^[2] . |
| In Vitro | Simvastatin sodium shows a inhibition of HMG-CoA reductase in human lymphoblasts and SV40 transformed MRCS fibroblasts ^[1] . Simvastatin sodium (100 μM) inhibits the Na ⁺ /H ⁺ antiport activity leading to a fall of intracellular pH and to a reduced cell proliferation. And the inhibitory effect is prevented by mevalonate but not dolichol or squalene ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| In Vivo | Simvastatin sodium (oral administration; 8 mg/kg; 18 days) reduces plasma cholesterol levels 33%, simvastatin can be used in combination with ezetimibe to treat dyslipidemia ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

REFERENCES

[1]. Corsini A, et al. Pharmacology of competitive inhibitors of HMG-CoA reductase. *Pharmacol Res.* 1995 Jan;31(1):9-27.

[2]. Andrew Marsh, et al. Simvastatin Sodium Salt and Fluvastatin Interact with Human Gap Junction Gamma-3 Protein. *PLoS One.* 2016 Feb 10;11(2):e0148266.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA